Consideration on the relation between the removal efficiency of levetiracetam and the clinical presentation by the difference in the dialysis treatment conditions

Consideration on the relation between the removal efficiency of levetiracetam and the clinical presentation by the difference in the dialysis treatment conditions - Consideration on the relation between the removal efficiency of levetiracetam and the clinical presentation by the difference in the dialysis treatment conditions

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042042

Enrollment

Registered

2020-11-01

Start date

2020-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Pre-dilution Online HDF (replacement amount 60L)Post dilution Online HDF (replacement amount 10L)Hemodialysis (HD) 4 weeks for each Dialysis number of times 12 times for each

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient I do REBECHIRASETAMU internal use of

Exclusion criteria

Exclusion criteria: The present dialysis treatment condition is a patient besides Pre-dilution On-line HDF A sleeping pill and a Antipsychotic taking medication regularly The patient who can't get consent in study participation The patient who judged that a doctor was improper in study participation

Design outcomes

Primary

Measure	Time frame
REBECHIRASETAMU blood level From change in dialysis method, 4 weeks later	—

Secondary

Measure	Time frame
Drowsiness by VAS and the score of the appetite From change in dialysis method, 4 weeks later	—

Countries

Japan

Contacts

Public ContactMasanori Isoda

Social medical corporation Kawashimakai Kawashima Hospital Clinical engineering operator

maisoda615@khg.or.jp088-631-0110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026